Amarin Corporation plc
NASDAQ:AMRNBiotechnology
+$0.29 today
- Market cap
- $233.09M
- Beta
- 0.82
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$1.62
Volume 0.08M
Average 0.07M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Amarin Corporation plc
NASDAQ:AMRN
Intrinsic Alpha fair value
Locked
Current Price
$11.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -16.7% | +2.3% (4yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -16.7% over three years. Forward estimates point to Revenue at +2.3% (4yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Alto Neuroscience, Inc. NYSE:ANRO | $1.18B | $29.54 | Not rated | -9.8 | +68.88% |
Silence Therapeutics plc NASDAQ:SLN | $936.65M | $19.83 | Not rated | -3.9 | +193.33% |
Lyell Immunopharma, Inc. NASDAQ:LYEL | $351.57M | $14.30 | Not rated | -1.1 | -23.76% |
Altimmune, Inc. NASDAQ:ALT | $319.98M | $1.65 | Not rated | -3.7 | -67.10% |
Larimar Therapeutics, Inc. NASDAQ:LRMR | $313.73M | $3.02 | Not rated | -1.8 | -11.80% |
DBV Technologies S.A. NASDAQ:DBVT | $263.50M | $11.02 | Not rated | -8.3 | -28.28% |
AC Immune S.A. NASDAQ:ACIU | $216.78M | $2.13 | Not rated | -2.9 | -30.82% |
Korro Bio, Inc. NASDAQ:KRRO | $196.29M | $13.61 | Not rated | -1.3 | +98.07% |
enGene Holdings Inc. NASDAQ:ENGN | $161.51M | $2.41 | Not rated | -1.8 | -75.00% |
Cellectis S.A. NASDAQ:CLLS | $118.86M | $1.18 | Not rated | -4.6 | -74.21% |
Continue the stock analysis
Jump to another research area for this company.